4.7 Review

Structural perspective of class B1 GPCR signaling

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 43, Issue 4, Pages 321-334

Publisher

CELL PRESS
DOI: 10.1016/j.tips.2022.01.002

Keywords

-

Funding

  1. National Natural Science Foundation of China [81872915, 82073904, 32071203, 81773792, 81973373, 21704064]
  2. National Science and Technology Major Project of China - Key New Drug Creation and Manufacturing Program [2018ZX09735-001, 2018ZX09711002-002-005, 2021ZD0203400]
  3. National Key Basic Research Program of China [2018YFA0507000]
  4. Ministry of Science and Technology of China [2018YFA0507002]
  5. Shanghai Municipal Science and Technology Commission Major Project [2019SHZDZX02]
  6. Strategic Priority Research Program of ChineseAcademy of Sciences [XDB37030103]
  7. Novo Nordisk-CAS Research Fund [NNCAS-2017-1-CC]
  8. Shanghai Science and Technology Development Funds [18ZR1447800, 18431907100]
  9. Young InnovatorAssociation of CAS [2018325]
  10. SA-SIBS Scholarship Program

Ask authors/readers for more resources

Class B1 G protein-coupled receptors have important functions in human physiology and disease pathology. Recent advances in cryo-electron microscopy and X-ray crystallography have provided detailed insights into their three-dimensional structures, ligand recognition, and receptor activation. These findings offer new avenues for developing improved therapeutic agents.
Class B1 G protein-coupled receptors (GPCRs) play important roles in human physiology and disease pathology. Using cryo-electron microscopy (cryo-EM) and X-ray crystallography, the 3D structures of all 15 members of this receptor subfamily have been determined in recent years at the near-atomic level. Although they share many structural commonalities, they show distinct features in terms of ligand recognition and receptor activation. In-depth structural analyses have yielded valuable insights into the N termini of both peptide hormones and cognate receptors, the outward movement of transmembrane helix 6 (TM6), the allosteric modulation sites located in the transmembrane domain (TMD), and the constitutive signaling bias mediated by receptor splice variants. These provide new directions for the design of better therapeutic agents, thereby making these targets more druggable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available